• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.

作者信息

Matsuoka Tasuku, Yamamoto Yurie, Yashiro Masakazu

机构信息

Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Institute of Medical Genetics, Osaka Metropolitan University, Osaka, Japan.

出版信息

Transl Cancer Res. 2025 Mar 30;14(3):1507-1510. doi: 10.21037/tcr-2024-2421. Epub 2025 Mar 20.

DOI:10.21037/tcr-2024-2421
PMID:40224980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11985196/
Abstract
摘要

相似文献

1
The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.HER2DX检测对早期HER2阳性乳腺癌患者病理反应和预后的预测价值：对PHERGain试验的评论
Transl Cancer Res. 2025 Mar 30;14(3):1507-1510. doi: 10.21037/tcr-2024-2421. Epub 2025 Mar 20.
2
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.曲妥珠单抗联合帕妥珠单抗治疗 HER2 阳性早期乳腺癌的 HER2DX 基因组分析：来自 PHERGain Ⅱ期试验的相关性分析。
Clin Cancer Res. 2024 Sep 13;30(18):4123-4130. doi: 10.1158/1078-0432.CCR-24-0464.
3
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.HER2阳性炎性乳腺癌中的HER2DX：相关见解及与非炎性乳腺癌的比较分析
ESMO Open. 2025 Feb;10(2):104100. doi: 10.1016/j.esmoop.2024.104100. Epub 2025 Jan 17.
4
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.用于预测早期HER2阳性乳腺癌病理反应和生存结果的新型HER2DX检测方法的开发与验证
EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3.
5
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.曲妥珠单抗和帕妥珠单抗新辅助治疗后 HER2 阳性/激素受体阳性乳腺癌的 HER2DX 基因组检测：来自 PerELISA 试验的相关性分析。
EBioMedicine. 2022 Nov;85:104320. doi: 10.1016/j.ebiom.2022.104320. Epub 2022 Oct 29.
6
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.多变量预后评分指导早期 HER2 阳性乳腺癌的全身治疗：一项回顾性研究及外部评估。
Lancet Oncol. 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2.
7
Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.HER2DX基因检测在HER2阳性乳腺癌治疗中的应用与挑战
Am J Cancer Res. 2024 Sep 15;14(9):4218-4235. doi: 10.62347/JWHA6355. eCollection 2024.
8
HER2DX genomic test in early-stage HER2-positive breast cancer.早期HER2阳性乳腺癌的HER2DX基因检测
ESMO Open. 2024 Dec;9(12):103987. doi: 10.1016/j.esmoop.2024.103987. Epub 2024 Nov 16.
9
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.曲妥珠单抗联合帕妥珠单抗与紫杉类药物新辅助治疗 ERBB2 阳性乳腺癌患者中 HER2DX 检测的评估。
JAMA Oncol. 2023 Jun 1;9(6):835-840. doi: 10.1001/jamaoncol.2023.0181.
10
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).早期 HER2 阳性乳腺癌中 HER2DX 的预后价值：瑞典癌症分析网络-乳腺数据集（SCAN-B）中 757 例患者的综合分析。
ESMO Open. 2024 Mar;9(3):102388. doi: 10.1016/j.esmoop.2024.102388. Epub 2024 Mar 4.

本文引用的文献

1
A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes-Bozyaka Experience.乳腺癌新辅助化疗的综合分析：不良事件、临床缓解率以及手术和病理结果——博齐亚卡经验
Cancers (Basel). 2025 Jan 7;17(2):163. doi: 10.3390/cancers17020163.
2
Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.评估肿瘤浸润淋巴细胞作为乳腺导管原位癌患者的预后生物标志物。
Breast Cancer Res Treat. 2024 Nov;208(1):9-18. doi: 10.1007/s10549-024-07466-9. Epub 2024 Aug 24.
3
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.
曲妥珠单抗联合帕妥珠单抗治疗 HER2 阳性早期乳腺癌的 HER2DX 基因组分析：来自 PHERGain Ⅱ期试验的相关性分析。
Clin Cancer Res. 2024 Sep 13;30(18):4123-4130. doi: 10.1158/1078-0432.CCR-24-0464.
4
Breast Cancer Screening and Prevention.乳腺癌筛查与预防
Ann Intern Med. 2023 Nov;176(11):ITC161-ITC176. doi: 10.7326/AITC202311210. Epub 2023 Nov 14.
5
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.HER2DX 与 HER2 阳性乳腺癌的病理完全缓解和生存结局的关联。
Ann Oncol. 2023 Sep;34(9):783-795. doi: 10.1016/j.annonc.2023.05.012. Epub 2023 Jun 9.
6
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.曲妥珠单抗联合帕妥珠单抗与紫杉类药物新辅助治疗 ERBB2 阳性乳腺癌患者中 HER2DX 检测的评估。
JAMA Oncol. 2023 Jun 1;9(6):835-840. doi: 10.1001/jamaoncol.2023.0181.
7
Deciphering breast cancer: from biology to the clinic.解读乳腺癌：从生物学到临床
Cell. 2023 Apr 13;186(8):1708-1728. doi: 10.1016/j.cell.2023.01.040. Epub 2023 Mar 16.
8
The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness.异质性的复杂本质及其在乳腺癌生物学和治疗反应中的作用。
Front Endocrinol (Lausanne). 2023 Feb 23;14:1083048. doi: 10.3389/fendo.2023.1083048. eCollection 2023.
9
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.曲妥珠单抗和帕妥珠单抗新辅助治疗后 HER2 阳性/激素受体阳性乳腺癌的 HER2DX 基因组检测：来自 PerELISA 试验的相关性分析。
EBioMedicine. 2022 Nov;85:104320. doi: 10.1016/j.ebiom.2022.104320. Epub 2022 Oct 29.
10
Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer).新辅助帕妥珠单抗治疗非转移性HER2阳性乳腺肿瘤：秘鲁多中心研究（NeoHer）
Mol Clin Oncol. 2022 Mar;16(3):70. doi: 10.3892/mco.2022.2503. Epub 2022 Jan 25.